SCHEMBL21709502

SCHEMBL21709502

CC1(C)c2ccccc2-c2c(N(c3ccccc3-c3ccccc3)c3nc(-c4cccc(-c5ccccc5)c4)nc4ccccc34)cccc21

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 8/20 0.40
CYP2D6 P10635 8/20 0.40
CYP3A4 P08684 7/20 0.40
CYP2C19 P33261 7/20 0.40
CLK4 Q9HAZ1 7/20 0.40
CYP2C9 P11712 5/20 0.40
HSD17B10 Q99714 4/20 0.40
USP2 O75604 3/20 0.40
ALOX15 P16050 3/20 0.40
MAPK1 P28482 2/20 0.40
TSHR P16473 6/20 0.40
ALDH1A1 P00352 4/20 0.40
LMNA P02545 3/20 0.40
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
ABCG2 Q9UNQ0 3/20 0.38
PDE5A O76074 3/20 0.38
ACP1 P24666 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.37
GLA P06280 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21709402 0.94 CYP2D6 (0.42) CYP1A2CYP2D6CYP3A4CYP2C19CLK4
SCHEMBL21709404 0.91 CYP2D6 (0.44) CYP1A2CYP2D6CYP3A4CYP2C19CLK4
SCHEMBL21709277 0.86 CYP2D6 (0.47) CYP1A2CYP2D6CYP3A4CYP2C19CLK4
SCHEMBL21709397 0.86 PDE5A (0.42) CYP1A2CYP2D6CYP3A4CYP2C19CLK4
SCHEMBL21709409 0.85 EGFR (0.36) CYP1A2CYP2D6CYP2C19CLK4MAPK1
SCHEMBL21709395 0.83 CYP1A2 (0.42) CYP1A2CYP2D6CYP3A4CYP2C19CLK4
SCHEMBL21709323 0.83 MEN1 (0.38) CYP1A2CYP2D6CYP3A4CYP2C19CLK4
SCHEMBL21709403 0.82 CYP2D6 (0.40) CYP1A2CYP2D6CYP3A4CYP2C19CLK4
SCHEMBL21709508 0.82 PDE5A (0.38) CYP1A2CYP2D6CYP3A4CYP2C19CLK4
SCHEMBL26002228 0.80 CA12 (0.39) CYP2C19CYP2C9HSD17B10MAPK1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200048207-A1 COMPOUNDS WITH ARYLAMINE STRUCTURES MERCK PATENT GMBH (DE) 2020-02-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200048207-A1 COMPOUNDS WITH ARYLAMINE STRUCTURES DDT, NAT1, INMT CYP1A2 64/4885CYP2D6 24/4885CYP3A4 108/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.